MX2021006778A - Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. - Google Patents

Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.

Info

Publication number
MX2021006778A
MX2021006778A MX2021006778A MX2021006778A MX2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A MX 2021006778 A MX2021006778 A MX 2021006778A
Authority
MX
Mexico
Prior art keywords
cancer
immunomodulation
treatment
novel approach
talabostat
Prior art date
Application number
MX2021006778A
Other languages
English (en)
Inventor
Vincent J O''neill
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of MX2021006778A publication Critical patent/MX2021006778A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona un régimen para tratar a un sujeto que padece cáncer de próstata mediante la administración de Talabostat o una sal farmacéuticamente aceptable de este y Pembrolizumab. La presente descripción se basa en el descubrimiento de que la combinación de Talabostat o una sal farmacéuticamente aceptable de este y Pembrolizumab en un régimen de tratamiento específico es una terapia muy eficaz para tratar a sujetos que padecen cáncer de próstata.
MX2021006778A 2018-12-10 2019-12-10 Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion. MX2021006778A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US201962924429P 2019-10-22 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Publications (1)

Publication Number Publication Date
MX2021006778A true MX2021006778A (es) 2021-07-15

Family

ID=71075816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006778A MX2021006778A (es) 2018-12-10 2019-12-10 Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.

Country Status (13)

Country Link
US (1) US20220089733A1 (es)
EP (1) EP3893869A4 (es)
JP (1) JP2022512158A (es)
KR (1) KR20210102259A (es)
CN (1) CN113260361A (es)
AU (1) AU2019396206A1 (es)
BR (1) BR112021011205A2 (es)
CA (1) CA3121270A1 (es)
IL (1) IL283742A (es)
MX (1) MX2021006778A (es)
SG (1) SG11202106129RA (es)
TW (1) TW202034955A (es)
WO (1) WO2020123496A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711380C2 (ru) 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
JP2023514056A (ja) * 2020-02-07 2023-04-05 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用した癌の治療レジメン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
RU2711380C2 (ru) * 2015-07-16 2020-01-16 Байоксэл Терапьютикс, Инк. Новый подход к лечению рака с применением иммуномодуляции
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2018129497A1 (en) * 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Predictive and diagnostic methods for prostate cancer
EP3630838A1 (en) * 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
US20220089733A1 (en) 2022-03-24
EP3893869A4 (en) 2022-08-17
CN113260361A (zh) 2021-08-13
CA3121270A1 (en) 2020-06-18
SG11202106129RA (en) 2021-07-29
BR112021011205A2 (pt) 2021-08-24
TW202034955A (zh) 2020-10-01
AU2019396206A1 (en) 2021-06-17
EP3893869A1 (en) 2021-10-20
WO2020123496A1 (en) 2020-06-18
JP2022512158A (ja) 2022-02-02
KR20210102259A (ko) 2021-08-19
IL283742A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
WO2017053889A3 (en) Flt3 directed car cells for immunotherapy
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2020009773A (es) Terapia de combinacion.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
PH12016502354A1 (en) Pharmaceutical composition
MX2017015896A (es) Agente anticancerigeno.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2020001727A (es) Terapia de combinacion.
MX2019015211A (es) Compuestos para el tratamiento de tnbc.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
MX2019013862A (es) Terapia de combinacion.
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
MX2021006778A (es) Metodo novedoso para el tratamiento del cancer mediante inmunomodulacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
MX2023007680A (es) Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2019003751A (es) Proteina terapeutica.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.